Monday, June 16, 2014

News: Possible New Type of Targeted Therapy for Pulmonary Hypertension

Reuters - Actelion Pharmaceuticals US, Inc. released today the initial, positive results from the Phase III GRIPHON study of selexipag in 1,156 patients with pulmonary arterial hypertension (PAH). Selexipag is the first non-prostacyclin analogue that acts as a stimulator for the prostaglandin receptor (IP).

Read article

No comments: